Home » Stocks » Repligen

Repligen Corporation (RGEN)

Stock Price: $175.84 USD -1.70 (-0.96%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $175.50 -0.34 (-0.19%) Oct 27, 7:55 PM

Stock Price Chart

Key Info

Market Cap 9.23B
Revenue (ttm) 302.47M
Net Income (ttm) 30.94M
Shares Out 52.50M
EPS (ttm) 0.60
PE Ratio 293.07
Forward PE 192.31
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $175.84
Previous Close $177.54
Change ($) -1.70
Change (%) -0.96%
Day's Open 178.44
Day's Range 175.17 - 180.84
Day's Volume 277,077
52-Week Range 76.75 - 180.84

More Stats

Market Cap 9.23B
Enterprise Value 8.94B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 52.50M
Float 48.47M
EPS (basic) 0.58
EPS (diluted) 0.60
FCF / Share 0.81
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.34%
FCF Yield 0.46%
Payout Ratio n/a
Shares Short 1.34M
Short Ratio 3.81
Short % of Float 2.77%
Beta 1.06
PE Ratio 293.07
Forward PE 192.31
P/FCF Ratio 217.93
PS Ratio 30.52
PB Ratio 8.42
Revenue 302.47M
Operating Income 45.30M
Net Income 30.94M
Free Cash Flow 42.36M
Net Cash 291.95M
Net Cash / Share 5.56
Gross Margin 50.46%
Operating Margin 14.98%
Profit Margin 10.20%
FCF Margin 14.01%
ROA 2.27%
ROE 3.13%
ROIC 10.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-3.32% downside)
Current: $175.84
Target: 170.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth39.28%37.38%35.1%25.14%31.45%-6.78%9.48%128.16%30.14%-
Gross Profit15110874.1957.4248.2935.5343.0135.1020.1715.46
Operating Income36.0825.9914.0119.2217.8512.7622.9611.38-0.37-5.77
Net Income21.4116.6228.3511.689.358.1716.0914.16-0.04-4.06
Shares Outstanding48.3443.7738.2333.5732.8832.5031.6730.9130.7830.75
Earnings Per Share0.440.370.720.340.280.250.500.45--0.13
EPS Growth18.92%-48.61%111.76%21.43%12%-50%11.11%---
Operating Cash Flow67.2232.7717.457.5215.0518.4025.9313.443.23-2.45
Capital Expenditures-23.15-12.78-5.45-4.28-2.63-5.60-4.64-1.26-0.52-0.60
Free Cash Flow44.0619.9912.003.2412.4312.8021.3012.182.71-3.05
Cash & Equivalents53719417414272.2258.9061.8240.2649.8353.33
Total Debt26310399.2595.27------
Net Cash / Debt27490.3374.5146.9672.2258.9061.8240.2649.8353.33
Book Value1,06061659216912311210484.1267.0966.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Repligen Corporation
Country United States
Employees 761
CEO Tony J. Hunt

Stock Information

Ticker Symbol RGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: RGEN


Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.